NEW YORK, July 2, 2012 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against the board
of directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the
"Company") (NASDAQ: AMLN) concerning the proposed acquisition of
the Company by Bristol-Myers Squibb Co. ("Bristol-Myers") in a
transaction valued at approximately $5.3
billion.
(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
)
On July 2, 2012, it was announced
that Amylin and Bristol-Myers have entered into a definitive
agreement pursuant to which Bristol-Myers will acquire
Amylin. Under the agreement, Amylin shareholders will receive
$31.00 in cash per share held.
The transaction price represents a scant 10% premium over Amylin's
June 29, 2012 closing price, and at
least one analyst has set a target price for Amylin stock of
$32.00 per share.
Our investigation concerns whether the Amylin board of directors
is fulfilling its fiduciary duties, maximizing the value of the
Company, disclosing all material benefits and costs, and obtaining
full and fair consideration for Company shareholders.
If you own Amylin shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Benjamin Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email:bsachsmichaels@hfesq.com
Website:http://www.hfesq.com
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising.© 2012 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP
(www.hfesq.com). Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP